CD4 and neoplasm: ,42 Due to the paucity of tumor-specific helper neoantigens identified in pre-clinical cancer models, it is currently unclear which type of CD4+ T cell antigen most improves anti-tumor vaccine efficacy: tumor-specific neoantigens or tumor-unrelated universal helper antigens.